Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)
← catalyst calendarNCT06691984 · readout in 866 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
707actual
Sites
164
Countries
Australia, Austria, Belgium +19
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-09 | actual | When the study began enrolling |
| Primary completion | 2029-01-02 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-07-30 | estimated | The whole study's end, after follow-up |
| First posted | 2024-11-18 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-15 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Castration-resistant Prostate Cancer
Interventions
- Drug: Xaluritamig
- Drug: Abiraterone
- Drug: Enzalutamide
- Drug: Cabazitaxel
Primary outcome
what the primary-completion date above is the date OFOverall Survival (OS)
measured Up to approximately 53 months
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed